Causal Relationships Between Gout and Hypertension Evaluated
Investigators explored the causality between the liability of gout on hypertension and the liability of hypertension on gout.
Investigators explored the causality between the liability of gout on hypertension and the liability of hypertension on gout.
Researchers assessed the incidence and potential risk factors for the development of
fenofibrate-associated nephrotoxicity in patients with gout.
Researchers sought to integrate serum metabolomics and lipidomics to identify biomarkers of organ involvement in systemic lupus erythematosus.
Researchers evaluated the clinical value of miR-124-3p and miR-337-3p in plasma to determine whether they could serve as biomarkers for systemic lupus erythematosus.
Researchers examined the associated changes in serum urate levels with health-related quality of life in patients with gout.
A team of investigators assessed patterns of statin therapy prescribed to patients with atherosclerotic cardiovascular disease with comorbid nondialysis chronic kidney disease.
Researchers investigated the safety and efficacy of oral methotrexate as co-therapy with pegloticase for sustained urate-lowering response.
Investigators compared the long-term effects of febuxostat on arterial stiffness and atherosclerosis in patients with hyperuricemia and gout.
Do patients who receive treatment with long-term immunosuppressive medications have worse outcomes when hospitalized with COVID-19?
The AHA released a statement focusing on the importance of managing cardiovascular risk factors in patients with type 2 diabetes.